↑↓ navigate ↵ open esc close
SELL TO STATE.
Start free trial
Germany TED / Vergabe.de contract award · ocds-ted-402266-2025

Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften

DAK-Gesundheit awarded €1 to Outlook Therapeutics Limited for Healthcare & Medical in June 2025 — one of 389 awards this buyer has made, in line with its typical award size.

Healthcare & Medical
24 Jun 2025
Award date
€1
Contract value

Buying agency

DAK-Gesundheit
389 Awards
€581K Avg award
Typical vs typical

Winning supplier

Outlook Therapeutics Limited
1 Award
1 Buyer
€1 Total won

Contract description

Germany – Pharmaceutical products – Arzneimittelrahmenrabattvertrag gemäß § 130a Abs. 8 bzw. § 130c Absatz 1 des Fünften Sozialgesetzbuchs - Lytenava (Wirkstoff: Bevacizumab gamma), ATC S01LA08

Premium

Related awards · DAK-Gesundheit

389 awards

The buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.

Tender no.SupplierAmountDateSector
Locked rows — unlock the full dataset below.

Premium · full dataset

See the full award context.

Competing bids, award margins and every related contract for DAK-Gesundheit and Outlook Therapeutics Limited — one subscription unlocks everything.

Sign Up Free →

Free account · cancel anytime · 14-day money-back

Sign Up